Knockdown of mutated H-Ras V12 expression induces chemosensitivity of hepatocellular carcinoma cells to cisplatin treatment in vitro and in nude mouse xenografts

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 2023-2030

  Meng, Fanjie ^a   Cao, Bin ^a   Feng, Zengli ^a   Ma, Shunmao ^a   Wang, Haigang ^a   Li, Yanshu ^a   Li, Hui ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Chemosensitivity; Cisplatin; H Ras V12; Hepatocellular carcinoma

Indexed keywords

CISPLATIN; GLYCINE; H RAS PROTEIN; PROTEIN KINASE B; RAS PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VALINE; ANTINEOPLASTIC AGENT; HRAS PROTEIN, HUMAN; PROTEIN P21; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BEL7402 CELL LINE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE CONSTRUCT; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; H RAS GENE; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SMMC7721 CELL LINE; TUMOR XENOGRAFT; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DRUG RESISTANCE; DRUG SCREENING; GENETICS; LIVER NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907289376     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3466     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global Cancer Statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Saxena N, Lahiri SS, Hambarde S and Tripathi RP: RAS: target for cancer therapy. Cancer Invest 26: 948-955, 2008.
3. Boguski MS and McCormick F: Proteins regulating Ras and its relatives. Nature 366: 643-654, 1993.
4. Bos JL: ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.
5. Bollag G and McCormick F: Regulators and effectors of ras proteins. Annu Rev Cell Biol 7: 601-632, 1991.
6. Sui G, Ma X, Liu S, Niu H and Dong Q: Study of the correlation between H-ras mutation and primary hepatocellular carcinoma. Oncol Lett 4: 779-782, 2012.
7. Lim KH and Counter CM: Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 8: 381-392, 2005.
8. Rotblat B, Ehrlich M, Haklai R and Kloog Y: The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol 439: 467-489, 2008.
9. Reuter C, Morgan M and Bergmann L: Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96: 1655-1669, 2000.
10. Méndez-Sánchez N, Vásquez-Fernández F, Zamora-Valdés D and Uribe M: Sorafenib, a systemic therapy for hepatocellular carcinoma. Ann Hepatol 7: 46-51, 2008.
11. Njoroge FG, Doll RJ, Vibulbhan B, et al: Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase. Bioorg Med Chem 5: 101-113, 1997.
12. Yang G, Thompson JA, Fang B and Liu J: Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene 22: 5694-5701, 2003.
13. Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
14. Paoluzzi L, Gonen M, Bhagat G, et al: The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112: 2906-2916, 2008.
15. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S and Zhang R: Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther 5: 1585-1592, 2006.
16. Sepp-Lorenzino L, Rands E, Mao X, et al: A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo. Cancer Res 64: 751-756, 2004.
17. Crowder C, Kopantzev E, Williams K, Lengel C, Miki T and Rudikoff S: An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth. Oncogene 22: 649-659, 2003.
18. Johnston SR: Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. Lancet Oncol 2: 18-26, 2001.
19. Tang Z, Qin L, Wang X, et al: Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J 111: 313-318, 1998.
20. Iida M, Iwata H, Inoue H, Enomoto M, Horie N and Takeishi K: Correlation between Bcl-2 overexpression and H-ras mutation in naturally occurring hepatocellular proliferative lesions of the B6C3F1 mouse. Toxicol Sci 56: 297-302, 2000.
21. Fleming JB, Shen GL, Holloway SE, Davis M and Brekken RA: Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 3: 413-423, 2005.
22. Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93: 1062-1074, 2001.
23. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
24. Friday BB and Adjei AA: Advances in targeting the Ras/Raf/MEK/Erk mitogen-Activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14: 342-346, 2008.
25. Diehl JA, Cheng M, Roussel MF and Sherr CJ: Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511, 1998.
26. Kip1through the phosphatidylinositol 3-kinase/AKT pathway. J Biol Chem 275: 39223-39230, 2000.
27. Pugazhenthi S, Nesterova A, Sable C, et al: Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response elementbinding protein. J Biol Chem 275: 10761-10766, 2000.
28. Bernhard EJ: Pancreatic cancer inhibition by specific knockdown of K-ras mutant allele expression. Cancer Biol Ther 6: 293-294, 2007.
29. Lto induce apoptosis in colon cancer cells. J Biol Chem 281: 16034-16042, 2006.
30. Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L and Dong Z: Regulation of PUMA-A by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25: 4056-4066, 2006.
31. Hemann MT, Zilfou JT, Zhao Z, Burgess DJ, Hannon GJ and Lowe SW: Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci USA 101: 9333-9338, 2004.
32. Villunger A, Michalak EM, Coultas L, et al: p53-And druginduced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036-1038, 2003.
33. Tsuruya K, Yotsueda H, Ikeda H, et al: Involvement of p53-transactivated Puma in cisplatin-induced renal tubular cell death. Life Sci 83: 550-556, 2008.